Compare SIBN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | CTMX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 596.2M |
| IPO Year | 2018 | 2015 |
| Metric | SIBN | CTMX |
|---|---|---|
| Price | $13.83 | $4.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $24.13 | $8.86 |
| AVG Volume (30 Days) | 512.4K | ★ 2.2M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,301,000.00 | ★ $138,103,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $14.95 | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | 21.53 | ★ 36.45 |
| 52 Week Low | $12.50 | $0.40 |
| 52 Week High | $21.89 | $6.35 |
| Indicator | SIBN | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 44.03 |
| Support Level | N/A | $3.83 |
| Resistance Level | $17.05 | $6.20 |
| Average True Range (ATR) | 0.75 | 0.32 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 21.39 | 17.65 |
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.